Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973269 · ClinicalTrials.gov registry record · Phase 2
DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
A Phase 2 study, sponsored by Revance Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02973269: Clinical Trial Phase 2 study, sponsored by Revance Therapeutics.
NCT02973269 is a Phase 2 study that was terminated before completion, run by Revance Therapeutics. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02973269, a Phase 2 study, was terminated before completion, sponsored by Revance Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
Primary Outcome
The American Orthopaedic Foot and Ankle Score (AOFAS) is a 9-item questionnaire that evaluates pain, function, and alignment of the foot and ankle. The total score ranges from 0 to 100, with lower scores representing greater pain and disability, and higher scores representing better function.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL daxibotulinumtoxin type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2017-05-31 |
| Phase | Phase 2 |
Why NCT02973269 stopped before completion
NCT02973269 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02973269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02973269 about?
NCT02973269 is a clinical study titled "DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis". The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.
What is the current status of trial NCT02973269?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-11-14. Estimated completion is 2017-05-31.
What interventions are being tested in trial NCT02973269?
The interventions under investigation include: Placebo (BIOLOGICAL), daxibotulinumtoxin type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02973269?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02973269's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI